OBJECTIVE:To observe clinical efficacy and safety of salmeterol and fluticasone propionate in the treatment of mod-erate and severe bronchial asthma. METHODS:98 patients with moderate and severe bronchial asthma were selected from our hospi-tal were included in the study and were randomly divided into control group(49 cases,3 cases withdrew from the test and 46 cases completed the test)and observation group(49 cases,2 cases withdrew from the test and 47 cases completed the test). Control group was given Budesonide aerosol preparation,1 dose,bid;observation group was given Salmeterol and fluticasone propionate inhala-tion,1 dose,bid. The treatment course lasted for 2 months. Clinical efficacy,lung function indexes,the time of clinical symptom disappearance,FEV1,PD20,ACT score,asthma attack times within half an year,EO%and ECP in serum and sputum,and the oc-currence of ADR were compared between 2 groups. RESULTS:After treatment,total effective rate of observation group was signifi-cantly higher than that of control group(95.73% vs. 76.09%);FVC,FEV1 and PEF and other indexes of 2 groups were increased significantly,and the observation group was significantly higher than the control group;the disappearance time of pulmonary rales, wheezing,dyspnea and cough in observation group were significantly shorter than in control group;PD20 and ACT score of 2 groups were significantly increased,ACT score of observation group was significantly higher than that of control group;EO% and ECP in serum and sputum of observation group were significantly lower than those of control group,there was statistical significance (P<0.05). Asthma attack times within half an year in observation was less than control group,there was no statistical significance (P>0.05). All ADRs disappeared after drug withdrawal. CONCLUSIONS:Therapeutic efficacy of salmeterol and fluticasone propio-nate is better than budesonide in the treatment of moderate and severe bronchial asthma,and can effectively improve lung function, shorten the time of clinical symptoms disapperance and reduce the level of inflammatory factor with and good safety.

OBJECTIVE:To compare the efficacy and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS:96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received reasonable diet control,low molecular weight heparin,Aspirin enteric-coated tablet,β-blockers,nitric acid lipids and other conventional treatment,but no vitamins and other antioxidant drugs. Based on it,observation group was orally given 10 mg Rosuvastatin tablet,once a day;control group was given 20 mg Atorvastatin capsule,once a day. The treatment course for both groups was 6 months. Clinical efficacy, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol(HDL-C),high-sensitivity C-reactive protein(hs-CRP)and left ventricular ejection fraction (LVEF) before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). Before treat-ment,there were no significant differences in the TC,TG,LDL-C,HDL-C,hs-CRP and LVEF between 2 groups(P>0.05). After treatment,TC,TG,LDL-C,HDL-C and hs-CRP in 2 groups were significantly lower than before,and TC,LDL-C and hs-CRP in observation group were lower than control group,HDL-C and LVEF in 2 groups were significantly higher than before,and observa-tion group was higher than control group,the differences were statistically significant (P<0.05). CONCLUSIONS:Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease,but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.

Objective To detect the expression of histone deacetylase 6 (HDAC6) and its significance in non-small cell lung cancer (NSCLC).Methods The expression of HDAC6 was measured by SP staining in 70 cases of NSCLC and 18 cases of normal lung tissues.Results Positive rate of HDAC6 immunostaining in NSCLC was 58.57％,which was significantly higher than 16.67％ in normal lung tissues(P ＜0.01 ).No correlation was found between HDAC6 expression and the age,sex,differentiated level,histological type ( P ＞0.05).But the expression level of HDAC6 was closely related to clinical stage and lymph node metastasis in NSCLC patients ( P ＜ 0.05 ).Conclusion HDAC6 over expression may be related to the pathogenesis and development of NSCLC.

Objective To investigate the significance of the soluble Apo-1/Fas(sApo-1/Fas) in differentiating tuberculous and malignant pleural effusion.Methods The level of sApo-1/Fas was detected by enzyme linked immunosorbent assay(ELISA).in serum and pleural effusion of 50 cases with malignant pleural effusion and 48 cases with tuberculous pleural effusion.Results The level of sApo-1/Fas in the serum and pleural effusion of malignant pleural effusion patients were ( 16.3 ± 2.5 ) μg/L and ( 38.6 ± 13.5) μg/L,significantly higher than those of tuberculous patients with pleural effusion( all P ＜ 0.05 ).The difference of rates of serum and pleural effusion in malignant pleural effusion and tuberculous pleural effusion patients was significant( P ＜ 0.05 ).The sensitivity,specificity and accuracy of sApo-1/Fas in serum and malignant pleural effusion were 66.0％ and 93.8％ and 79.6％.Conclusion The detecting of sApo-1/Fas may play some role in differentiating tuberculous and malignant pleural effusion.

ObjectiveTo explore the levels and clinical significance of osteopontin (OPN) in serum of patients with non-small cell lung cancer (NSCLC).MethodsOPN levels of 102 cases of NSCLC,42 cases of benign lung disease and 30 cases of healthy control were measured by enzyme-linked immunosorbent assay(ELISA).ResultsThe serum OPN levels of NSCLC were significantly higher than those of benign lung disease group and healthy control group (P＜0.01).The levels of OPN in serum were compared between different gender,age,histological differentiation and pathological type groups,but there were no significant difference (P＞0.05).The serum OPN levels of Ⅲ - Ⅳ stage NSCLC patients,with lymph node metastasis,before operation patients,recrudescent patients,survival below 3 years patients were relatively higher than that in the patients with Ⅰ - Ⅱ stage,without lymph node metastasis,after operation,no recrudescent,survival over 3 years patients,and the differences were significant (P＜0.01).ConclusionsOPN levels in serum reflected the severity of the disease,which can be used to determine the effects of surgery and monitor recurrence and evaluate prognosis.

ObjectiveTo detect serum soluble B7-H4 (sB7-H4) levels in patients with non-small cell lung cancer ( NSCLC ) and explore its clinical significances.MethodsThe sB7-H4 levels the sera of in 102 NSCLC patients,60 benign lung disease patients and 90 healthy controls were determined by ELISA.The relation between serum sB7-H4 levels and NSCLC of pathological staging was analyzed by use of t test.ResultsThe serum sB7-H4 levels in NSCLC,benign lung disease and heathy control groups were (45.61 ±5.67 ),( 30.14 ± 3.51 ) and ( 28.52 ± 4.76 ) μg/L,respectively.The levels of NSCLC group were significantly higher than those of benign lung disease and healthy control groups ( t =2,59 and 3.61,P ＜ 0.05 ).The serum sB7-H4 levels of Ⅲ/IV stage NSCLC patients ( 63.93 t 4.76 ) μgL,with lymph node metastasis (61.73 ±3.97) μg/L and before operation patients (63.29 ±6.19) μg/L were relatively higher thanthose inthe Ⅰ/Ⅱ stage(35.12 ± 3.88 )μg/L, without lymphnode metastasis (40.26 ± 5.39 ) μg/L,after operation ( 40.51± 4.08 ) μg/L.There were significant difference ( t =6.78,5.73 and 3.67,P ＜ 0.05 ).Conclusions Serum sB7-H4 of NSCLC patients increases significantly and correlates with clinical stages and therapeutic conditions.Detecting on sB7-H4 is helpful for lung cancer diagnosis and therapeutic effect evaluation.

Objective To study the relationship between DNA methylation inhibitor and histone deacetylase inhibitor (HDACI) with HLA-B27 gene expression. Methods Hela-HLA-B27 promoter stable cell line was developed as the first step and followed by detecting the effect of DNA methylation inhibitor(5-Aza-CdR) and HDACI. The synergetic effect of HDACI and cytokines as well as the effect of anti-TNF-α antibody, anti-IFN-β antibody, anti-IFN-γ antibody and Infiximab on HLA-B27 promoter activity were tested by measuring luciferase value. Then HLA-B27 mRNA expression level in CCL6-B27 genomic DNA stable cell line was measured by real-time PCR. Results Sodium butyrate(NaB) and valproic acid(VPA)could significantly up-regulate HLA-B27 promoter activity at 24 h (24.0±1.7) times, ( 17.4±2.2 ) times respectively,(P＜0.05). The synergetic effect between VPA with TNF-α, IFN-α, IFN-β, IFN-γ and PMA on HLA-B27 promoter activity was found. None of the antibody could inhibit the effect of HDACI. It also showed that NaB,TSA, VPA and 5-Aza-CdR could significantly increase HLA-B27 mRNA expression in CCL6-B27 stable cell line. Conclusion DNA methylation and HDACI can up-regulate HLA-B27 gene expression level.

Purpose:This report evaluate whether the single-agent therapy with vinorelbine (V group) may obtain a high response rate, with acceptable toxicity and improvement in survival and quality of life, comparing with the therapy with Kanglaite (a traditional Chinese medicine) (K group) and other supportive care among elderly patients.Methods:Forty patients with advanced NSCLC were included,20 of whom were allocated to receive continual infusional NVB 7.5mg/m 2 /24hr delivered via a central venous line on days 1-5, and NVB 7.5mg /m 2 was given as a 20 min intravenous infusion on days 1 every 3 weeks; 20 of whom were allocated to receive infusional Kanglaite 200 ml on days 1-20 every month. Patients received a minimum of two courses unless progressive disease was detected. Results:V group: CR 0,PR 7,CR+PR 35%(7/20), median survival time was 7.2 months and projected 1-year survival was 25%; K group:CR 0,PR2,CR+PR 10%(2/20),median survival time was 4.8 months and projected 1-year survival was 5%. Conclusions:In elderly patients with NSCLC, single-agent vinorelbine treatment is associated with better effective,better survival and improved quality of life than Kanglaite .Its toxicity is mild and acceptable.

AIM:To assess the effect of seven cytokines on transcriptional regulation of HLA-B27 promoter, NF-?B and ISRE cis-element activity in HeLa cells.METHODS: HeLa-HLAB27 promoter stable cell line was constructed. The HeLa-B27 promoter stable cell line, HeLa-NF-?B stable cell line and HeLa cells transfected with pISRE-luc were cultured with different cytokines (IL-1?, IL-1?, TNF-?, IFN-?, IFN-?, IFN-? and TGF-?).RESULTS: TNF-?, IFN-?, IFN-? and IFN-? increased the B27 promoter activity at 96 h. The strongest inducer was IFN-?, the luciferase activity increased by 5.4 times. TNF-?, IL-1? and IL-1? also induced the NF-?B activity at 8 h (increased around 30 times). IFN-? and IFN-? increased the interferon-stimulated response element(ISRE) activity 10 times at 6 h.CONCLUSION: TNF-? and interferons increase the B27 promoter activity. IFN-? might play an important role in the pathogenesis of B27 related diseases.

AIM:To screen the effective chemicals,which can suppress the promoter activity of the HLA-B2705 gene as potential therapeutic agents.METHODS:The HeLa-HLA-B27,293T-HLA-B27 stable transfectants were used to monitor the effect of 12 264 chemicals through high throughput screening(HTS).Chemicals which regulates HLA-B*2705 promoter activity more than 150% or less than 60% were picked out for the further IC50/EC50 and cell viability detection.RESULTS:(1)The primary screening used by 293T-HLA-B27 stable transfectant yielded about 5.1% hits which either suppressed(556 chemicals)or enhanced(68 chemicals)the HLA-B*2705 promoter activity.(2)A reconfirmation screening was carried out with these 624 of the candidates using transfected HeLa-HLA-B27 cells.Seventy hits were confirmed.(3)Based on the bioinformatics of those positive hits,40 chemicals were selected for in-depth analysis by dose-response experiment and IC50/EC50 detection.Six suppressors showed potential pharmacological activities.Interestingly,two suppressors(celastrol and pristimerin)are derived from Leigongteng,a herbal medicine already used for several decades for treatment of immune regulatory and inflammatory diseases.Four active chemicals were computer designed with no relevance to the above structures.CONCLUSION:Chinese traditional herb Nansheteng and Leigongteng might be the potential drugs for HLA-B27 positive patients.These results provide new direction for research in both the therapeutics and the pathogenesis of spondyloarthritis.